Stewart Alan Factor
Affiliations: | Emory University, Atlanta, GA |
Area:
Movement DisordersGoogle:
"Stewart Factor"Mean distance: 53433
Parents
Sign in to add mentor| William J. Weiner | grad student | 1986-1988 | Miller School of Medicine, University of Miami |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Espay AJ, Guskey MT, Norton JC, et al. (2018) Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Movement Disorders : Official Journal of the Movement Disorder Society |
| Fox SH, Metman LV, Nutt JG, et al. (2017) Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society |
| McGarry A, McDermott M, Kieburtz K, et al. (2016) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology |
| Frank S, Testa CM, et al. (2016) Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. Jama. 316: 40-50 |
| Factor SA, Hatcher-Martin JM, Morse AS, et al. (2016) Freezing of gait that disappears: Should there be rest before rehab? Parkinsonism & Related Disorders |
| Comella CL, Perlmutter JS, Jinnah HA, et al. (2016) Clinimetric testing of the comprehensive cervical dystonia rating scale. Movement Disorders : Official Journal of the Movement Disorder Society |
| Carvalho JO, Long JD, Westervelt HJ, et al. (2016) The impact of oculomotor functioning on neuropsychological performance in Huntington disease. Journal of Clinical and Experimental Neuropsychology. 38: 217-226 |
| Sampat R, Young S, Rosen A, et al. (2016) Potential mechanisms for low uric acid in Parkinson disease Journal of Neural Transmission. 1-6 |
| Mata IF, Jang Y, Kim CH, et al. (2015) The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Molecular Neurodegeneration. 10: 50 |
| O'Brien CF, Jimenez R, Hauser RA, et al. (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1681-7 |